Search

EHA Guidelines by Topic

AL Amyloidosis
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines (2021)
Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group (2022)
Anemia
Recommendations regarding splenectomy in hereditary hemolytic anemias (2017)
Management of…

Read more

Guidelines endorsed by EHA

EHA will not accept endorsement requests until the end of 2025.

Read more

Immunoglobulin shortages in the spotlight: EMA, SUPPLY and the SoHO Regulation

EMA executive director Emer Cooke welcoming participants including EHA at the Shortages Workshop, March 1

 

Shortages of immunoglobulins and the need to increase and sustain plasma supplies have moved to the center of the EU policy and regulatory stage.

Read more

TARGETING THE JAK-STAT PATHWAY IN MALIGNANT AND NON-MALIGNANT CELLS IN MYELOPROLIFERATIVE NEOPLASMS

Myeloproliferative neoplasms (MPN) are clonal blood disorders characterized by excessive production of mature blood cells. Patients present with large spleens, systemic symptoms, and high levels of circulating inflammatory cytokines.

Read more

EHA-AHA Hematology Tutorial on Lymphoid Malignancies

Dates: October 18-20, 2019
Location: Yerevan, Armenia
Chairs: G Gaidano, S Danielyan, Y Hakobyan

2019 marks the 3rd time EHA is organizing a tutorial in collaboration with the Armenian Hematology Association (AHA), this time on “Lymphoid Malignancies”.

Read more

European Scientific foundation for Laboratory Hemato Oncology (ESLHO)

The objectives of ESLHO are to promote the continuous innovation and standardization of laboratory diagnostics focused on lymphoid malignancies, as well as to facilitate quality control and education in this field.

Read more